Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. Show more

Location: 480 Arsenal Way, Watertown, MA, 02472, United States | Website: https://acrivon.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

41.39M

52 Wk Range

$1.05 - $10.16

Previous Close

$1.35

Open

$1.34

Volume

110,487

Day Range

$1.31 - $1.34

Enterprise Value

-108.8M

Cash

149.6M

Avg Qtr Burn

-17.03M

Insider Ownership

20.78%

Institutional Own.

55.04%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date